Granisetron: An Update on its Clinical Use in the Management of Nausea and Vomiting
Tóm tắt
Nausea and vomiting are typical side effects of cytotoxic therapy and some surgical procedures. These symptoms can represent a major therapeutic challenge and, if inadequately controlled by antiemetic treatment, will result in increased mortality, morbidity, and health care costs. However, the management of nausea and vomiting has improved greatly in recent years following the introduction of the 5-HT3-receptor antagonists, known as ‘setrons.’ In light of recent developments in antiemetic care, including the approval of the first neurokinin-1-receptor antagonist aprepitant (Emend®; Merck and Company, Inc.; West Point, PA) and a new 5-HT3 receptor antagonist palonosetron (Aloxi®; MGI Pharma; Minneapolis, MN), this article provides an update on the clinical experience gained with the 5-HT3-receptor antagonist granisetron (Kytril®; Roche Laboratories, Inc.; Nutley, NJ) for the management of chemotherapy-induced, radiation-induced, and postoperative nausea and vomiting, and also reviews its use in special patient populations. Granisetron is a potent and highly selective 5-HT3-receptor antagonist that has little or no affinity for other receptors, a characteristic that is thought to underlie the favorable side-effect and safety profiles of this agent. Extensive clinical trial data have shown granisetron to be an effective and well-tolerated agent for the treatment of nausea and vomiting in the oncology and surgical settings. Granisetron has also been shown to be effective and well tolerated in special populations, such as patients refractory to antiemetic treatment, patients with hepatic or renal impairment, and children. Data also suggest that its safety profile and minimal potential for drug-drug interactions would make it an antiemetic agent of choice for elderly cancer patients.
Từ khóa
Tài liệu tham khảo
Laszlo, 1983, Antiemetics and Cancer Chemotherapy
O'Brien, 1993, Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres, CMAJ, 149, 296
Sussman, 1995, Reactions of patients to the diagnosis and treatment of cancer, Anticancer Drugs, 6, 4, 10.1097/00001813-199502001-00002
Osoba, 1997, Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group, Support Care Cancer, 5, 307, 10.1007/s005200050078
1999, ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery, Am J Health Syst Pharm, 56, 729, 10.1093/ajhp/56.8.729
1998, Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC), Ann Oncol, 9, 811, 10.1023/A:1008471812316
Blower, 1995, A pharmacologic profile of oral granisetron (Kytril tablets), Semin Oncol, 22, 3
Wijngaarden, 1990, The concept of selectivity in 5-HT receptor research, Eur J Pharmacol, 138, 301, 10.1016/0922-4106(90)90190-9
Perez, 1998, Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study, J Clin Oncol, 16, 754, 10.1200/JCO.1998.16.2.754
Perez, 1998, Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy, Cancer J Sci Am, 4, 52
Aapro, 1993, Methodological issues in antiemetic studies, Invest New Drugs, 11, 243, 10.1007/BF00874423
Kamanabrou, 1992, Intravenous granisetron—establishing the optimal dose. The Granisetron Study Group, Eur J Cancer, 28A, S6, 10.1016/0959-8049(92)90629-G
Navari, 1994, Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin, J Clin Oncol, 12, 2204, 10.1200/JCO.1994.12.10.2204
Navari, 1995, Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group, J Clin Oncol, 13, 1242, 10.1200/JCO.1995.13.5.1242
Lehoczky, 1999, About the antiemetic effectivity of granisetron in chemotherapy-induced acute emesis: a comparison of results with intravenous and oral dosing, Neoplasma, 46, 73
Bleiberg, 1995, Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study, Clin Ther, 17, 38, 10.1016/0149-2918(95)80005-0
Burris, 1996, Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy, Cancer J Sci Am, 2, 85
Heron, 1994, Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group, Ann Oncol, 5, 579, 10.1093/oxfordjournals.annonc.a058927
Maisano, 1995, Efficacy of two oral dose regimens of granisetron, Anticancer Res, 15, 2287
Ettinger, 1996, A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy, Cancer, 78, 144, 10.1002/(SICI)1097-0142(19960701)78:1<144::AID-CNCR20>3.0.CO;2-Z
Gralla, 1998, Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy, J Clin Oncol, 16, 1568, 10.1200/JCO.1998.16.4.1568
Aapro, 2003, A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis, Ann Oncol, 14, 291, 10.1093/annonc/mdg075
Martin, 1997, Single-dose 1 mg oral granisetron (G) is less costly and as effective as intravenous ondansetron (O) in controlling nausea (N) and vomiting (V) from moderately emetogenic chemotherapy, Proc Am Soc Clin Oncol, 16, 76a
Markman, 1998, Low-dose oral granisetron (1 mg) plus intravenous dexamethasone: efficacy in gynecologic cancer patients receiving carboplatin-based chemotherapy, Gynecol Oncol, 71, 113, 10.1006/gyno.1998.5168
Herrington, 2000, Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy, Pharmacotherapy, 20, 1318, 10.1592/phco.20.17.1318.34894
Hesketh, 2000, Antiemetic efficacy of single-dose oral granisetron (1 mg vs 2 mg) with moderately emetogenic chemotherapy, Cancer J, 6, 157
Lehoczky, 1998, Report on the antiemetic effectivity of a single 1 mg oral granisetron in moderately emetogenic chemotherapies of gynecological malignancies, Eur J Gynaecol Oncol, 19, 449
Campos, 2001, Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone, J Clin Oncol, 19, 1759, 10.1200/JCO.2001.19.6.1759
Hesketh, 2003, Two randomized, double-blind, placebo controlled trials of the oral NK1 antagonist aprepitant for the prevention of chemotherapy induced nausea and vomiting, Support Care Cancer, 11, 390
Chawla, 2003, Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting, Cancer, 97, 2290, 10.1002/cncr.11320
Koeller, 2002, Antiemetic guidelines: creating a more practical treatment approach, Support Care Cancer, 10, 519, 10.1007/s00520-001-0335-y
Gralla, 1999, Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology, J Clin Oncol, 17, 2971, 10.1200/JCO.1999.17.9.2971
Chang, 1997, Comparison of intravenous granisetron with metoclopramide plus dexamethasone in the prevention of nausea and vomiting associated with emetogenic cytotoxic chemotherapy, Kaohsiung J Med Sci, 13, 97
Park, 1997, A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy, Am J Clin Oncol, 20, 569, 10.1097/00000421-199712000-00007
Guillem, 1998, High efficacy of oral granisetron in the total control of cyclophosphamide-induced prolonged emesis, Proc Am Soc Clin Oncol, 17, 46a
Raja, 1999, Prospective comparative study of 5HT-3 antagonists in moderately emetogenic therapy, Proc Am Soc Clin Oncol, 18, 604a
Yalçin, 1999, Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy: a randomized study, Am J Clin Oncol, 22, 94, 10.1097/00000421-199902000-00023
Öge, 2000, Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin, J Chemother, 12, 105
Peschel, 2003, Single IV dose of palonosetron (PAL), a potent 5-HT3 receptor antagonist (RA), demonstrates sustained prevention of nausea and vomiting for 5 days following moderately emetogenic chemotherapy (MEC), Proc Am Soc Clin Oncol, 22, 760
Rubenstein, 2003, Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for prevention of acute & delayed chemotherapy-induced nausea and vomiting (CINV): combined results of two phase III trials, Proc Am Soc Clin Oncol, 22, 729
Aapro, 2003, Palonosetron (PALO) is more effective than ondansetron (OND) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC): results of a phase III trial, Proc Am Soc Clin Oncol, 22, 726
Zofran® (ondansetron hydrochloride) US Product Information
Lindley, 2000, Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis, Am J Health Syst Pharm, 57, 1685, 10.1093/ajhp/57.18.1685
Bubalo, 2001, Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation, Biol Bone Marrow Transplant, 7, 439, 10.1016/S1083-8791(01)80011-2
Grote, 1997, Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group, Cancer J Sci Am, 3, 45
Minton, 1994, Volunteer models for predicting antiemetic activity of 5-HT3-receptor antagonists, Br J Clin Pharmacol, 37, 525, 10.1111/j.1365-2125.1994.tb04298.x
Kirchner, 1993, Early clinical trial of MDL 73.147 EF: a new 5-HT3-receptors antagonist for the prevention of chemotherapy-induced nausea and vomiting, Ann Oncol, 4, 481, 10.1093/oxfordjournals.annonc.a058558
Diemunsch, 2000, Potential of substance P antagonists as antiemetics, Drugs, 60, 533, 10.2165/00003495-200060030-00002
Hunter, 1991, Granisetron, a selective 5-HT3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation, Bone Marrow Transplant, 7, 439
Prentice, 1995, Granisetron in the prevention of irradiation-induced emesis, Bone Marrow Transplant, 15, 445
Belkacemi, 1996, Total body irradiation prior to bone marrow transplantation: efficacy and safety of granisetron in the prophylaxis and control of radiation-induced emesis, Int J Radiat Oncol Biol Phys, 36, 77, 10.1016/S0360-3016(96)00284-2
Orchard, 1999, A prospective randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation, Biol Blood Marrow Transplant, 5, 386, 10.1016/S1083-8791(99)70015-7
Logue, 1991, The antiemetic effect of granisetron in lower hemibody radiotherapy, Clin Oncol (R Coll Radiol), 3, 247, 10.1016/S0936-6555(05)80871-4
Spitzer, 2000, Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation, Bone Marrow Transplant, 26, 203, 10.1038/sj.bmt.1702479
Lerman, 1992, Surgical and patient factors involved in postoperative nausea and vomiting, Br J Anaesth, 69, 24S, 10.1093/bja/69.supplement_1.24S
Carroll, 1994, Costs incurred by outpatient surgical centers in managing postoperative nausea and vomiting, J Clin Anesth, 6, 364, 10.1016/S0952-8180(05)80004-2
Mikawa, 1995, The antiemetic efficacy of prophylactic granisetron in gynecologic surgery, Anesth Analg, 80, 970
Fujii, 1998, Prophylactic oral antiemetics for preventing postoperative nausea and vomiting: granisetron versus domperidone, Anesth Analg, 87, 1404
Fujii, 1998, Preoperative oral granisetron prevents postoperative nausea and vomiting, Acta Anaesthesiol Scand, 42, 653, 10.1111/j.1399-6576.1998.tb05297.x
Fujii, 1999, Granisetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting after thyroidectomy, Laryngoscope, 109, 664, 10.1097/00005537-199904000-00028
Fujii, 2000, Randomized clinical trial of granisetron, droperidol and metoclopramide for the treatment of nausea and vomiting after laparoscopic cholecystectomy, Br J Surg, 87, 285, 10.1046/j.1365-2168.2000.01393.x
Fujii, 2001, Prophylaxis with oral granisetron for the prevention of nausea and vomiting after laparoscopic cholecystectomy: a prospective randomized study, Arch Surg, 136, 101, 10.1001/archsurg.136.1.101
Fujii, 2001, Preoperative oral granisetron for the prevention of postoperative nausea and vomiting after breast surgery, Eur J Surg, 167, 184, 10.1080/110241501750099339
Mattioli, 1998, Oral granisetron as prophylaxis for nausea and vomiting during fluorescein angiography. A multicentre, double-blind, randomised, parallel group, placebo-controlled study, Minerva Anestesiol, 64, 553
Fujii, 2002, Preoperative oral granisetron for the prevention of vomiting following paediatric surgery, Paediatr Anaesth, 12, 267, 10.1046/j.1460-9592.2002.00823.x
Taylor, 1997, A double-blind, parallel-group, placebo-controlled, dose-ranging, multicenter study of intravenous granisetron in the treatment of postoperative nausea and vomiting in patients undergoing surgery with general anesthesia, J Clin Anesth, 9, 658, 10.1016/S0952-8180(97)00190-6
Yancik, 2001, Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base, J Clin Oncol, 19, 1147, 10.1200/JCO.2001.19.4.1147
Yancik, 1997, Cancer burden in the aged: an epidemiologic and demographic overview, Cancer, 80, 1273, 10.1002/(SICI)1097-0142(19971001)80:7<1273::AID-CNCR13>3.0.CO;2-4
Jörgensen, 2001, Prescription drug use, diagnoses, and healthcare utilization among the elderly, Ann Pharmacother, 35, 1004, 10.1345/aph.10351
Dilly, 1994, Granisetron (Kytril) clinical safety and tolerance, Semin Oncol, 21, 10
Hesketh, 2000, Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting, Cancer Invest, 18, 163, 10.3109/07357900009038248
Perez, 1996, Intravenous (IV) granisetron vs ondansetron in the prevention of cyclophosphamide-doxorubicin-induced emesis in breast cancer patients: a double-blind crossover study, Proc Am Soc Clin Oncol, 15, 543a
Audhuy, 1996, A double-blind randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy, Eur J Cancer, 32A, 807
Wei, 1995, Cardiovascular comorbidity in the older cancer patient, Semin Oncol, 22, 9
Gridelli, 2003, Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial, J Natl Cancer Inst, 95, 362, 10.1093/jnci/95.5.362
Cowan, 1991, Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group Study, J Natl Cancer Inst, 83, 1077, 10.1093/jnci/83.15.1077
Faulds, 1991, Mitoxantrone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer, Drugs, 41, 400, 10.2165/00003495-199141030-00007
Perez, 1998, A risk-benefit assessment of serotonin 5-HT3 receptor antagonists in antineoplastic therapy-induced emesis, Drug Saf, 18, 43, 10.2165/00002018-199818010-00004
Upward, 1990, The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist, Eur J Cancer, 26, S12
Boike, 1997, Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults, Am J Health Syst Pharm, 54, 1172, 10.1093/ajhp/54.10.1172
Carmichael, 1995, An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease, Cancer Chemother Pharmacol, 37, 134, 10.1007/BF00685640
Jantunen, 1996, Effects of granisetron with doxorubicin or epirubicin on ECG intervals, Cancer Chemother Pharmacol, 37, 502, 10.1007/s002800050420
Gray, 1996, Granisetron shows no pro-arrhythmic effect in normal subjects during or after exercise in a hot environment, Aviat Space Environ Med, 67, 759
Aapro, 2003, Rapid intravenous administration of granisetron prior to chemotherapy is not arrhythmogenic: results of a pilot study, Eur J Cancer, 39, 927, 10.1016/S0959-8049(03)00120-5
Carmichael, 2004, The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy, Cancer Chemother Pharmacol, 53, 123, 10.1007/s00280-003-0689-6
Carmichael, 2003, High-dose i.v. granisetron for the prevention of chemotherapy-induced emesis: cardiac safety and tolerability, Anticancer Drugs, 14, 739, 10.1097/00001813-200310000-00009
Natural Medicines Comprehensive Database
May, 1977, Drug interactions and multiple drug administration, Clin Pharmacol Ther, 22, 322, 10.1002/cpt1977223322
Karas, 1981, The potential for drug interactions, Ann Emerg Med, 10, 627, 10.1016/S0196-0644(81)80085-6
Flockhart, Clinically used drugs metabolized by cytochrome P450
Anonymous, 2000, Cytochrome P450
Hayes, The cytochrome P-450 enzyme system
Bloomer, 1994, Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron, Br J Clin Pharmacol, 38, 557, 10.1111/j.1365-2125.1994.tb04397.x
Dixon, 1995, Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans, Drug Metab Dispos, 23, 1225
Blower, 2002, 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications, Cancer J, 8, 405, 10.1097/00130404-200209000-00012
Sanwald, 1996, Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron: comparison with other indole-containing 5-HT3 antagonists, Drug Metab Dispos, 24, 602
Herrstedt, 18–21, 2003, The development of a new 5-HT3-receptor antagonist: from pharmacology to clinics, Presented at the MASCC/ISOO Meeting
Kaiser, 2002, Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes, J Clin Oncol, 20, 2805, 10.1200/JCO.2002.09.064
Marez, 1997, Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution, Pharmacogenetics, 7, 193, 10.1097/00008571-199706000-00004
Relling, 1991, Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects, Clin Pharmacol Ther, 50, 308, 10.1038/clpt.1991.141
London, 1997, Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County, Carcinogenesis, 18, 1203, 10.1093/carcin/18.6.1203
Evans, 1980, A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population, J Med Genet, 17, 102, 10.1136/jmg.17.2.102
Griese, 1998, Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population, Pharmacogenetics, 8, 15, 10.1097/00008571-199802000-00003
Kim, 2003, Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects, Eur J Clin Pharmacol, 59, 111, 10.1007/s00228-003-0595-1
Cagnoni, 1999, Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics, Bone Marrow Transplant, 24, 1, 10.1038/sj.bmt.1701832
Gilbert, 1998, Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer, Cancer Chemother Pharmacol, 42, 497, 10.1007/s002800050851
2003, Emend® Prescribing Information
Blum, 2003, Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects, Clin Ther, 25, 1407, 10.1016/S0149-2918(03)80128-5
Sigsgaard, 2000, Antiemetic efficacy of a combination therapy with granisetron plus prednisolone plus the dopamine D2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy, Support Care Cancer, 8, 233, 10.1007/s005200050291
Aapro, 1994, The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: the effect of granisetron, Br J Cancer, 69, 957, 10.1038/bjc.1994.185
Terrey, 1996, The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. The Granisetron Study Group, Eur J Clin Res, 8, 281
Carmichael, 1998, Use of granisetron in patients refractory to previous treatment with antiemetics, Anticancer Drugs, 9, 381, 10.1097/00001813-199806000-00002
Wit, 2001, Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy, Br J Cancer, 85, 1099, 10.1054/bjoc.2001.2045
Blower, 2002, Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?, Br J Cancer, 86, 1662, 10.1038/sj.bjc.6600313
Wit, 2003, Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics, Br J Cancer, 88, 1823, 10.1038/sj.bjc.6601033
Krengli, 1996, [The use of granisetron per os in radiotherapy-induced emesis.], Minerva Med, 87, 605
Palmer, 1994, Efficacy and safety of granisetron (Kytril) in two special patient populations: children and adults with impaired hepatic function, Semin Oncol, 21, 22
Aapro MS; Perugia Consensus; Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC), 2002, How do we manage patients with refractory or breakthrough emesis?, Support Care Cancer, 10, 106, 10.1007/s005200100288
Kytril® granisetron hydrochloride US Prescribing Information (injection and tablets)
Pinkerton, 1993, IV granisetron in children receiving highly emetogenic chemotherapy: a double-blind dose-ranging study, Eur J Cancer, 29A, S200a, 10.1016/0959-8049(93)91742-4
Komada, 1999, A randomised dose-comparison trial of granisetron in preventing emesis in children with leukaemia receiving emetogenic chemotherapy, Eur J Cancer, 35, 1095, 10.1016/S0959-8049(99)00071-4
Tsuchida, 1999, Effects of granisetron in children undergoing high-dose chemotherapy: a multi-institutional, cross-over study, Int J Oncol, 4, 673
Craft, 1995, Granisetron as antiemetic therapy in children with cancer, Med Pediatr Oncol, 25, 28, 10.1002/mpo.2950250107
Hählen, 1995, A randomized comparison of intravenously administered granisetron versus chlorpromazine plus dexamethasone in the prevention of ifosfamide-induced emesis in children, J Pediatr, 126, 309, 10.1016/S0022-3476(95)70568-6
Fujii, 2001, Prevention of vomiting after tonsillectomy in children: granisetron versus ramosetron, Laryngoscope, 11, 255, 10.1097/00005537-200102000-00013
Fujii, 2001, Ramosetron compared with granisetron for the prevention of vomiting following strabismus surgery in children, Br J Ophthalmol, 85, 670, 10.1136/bjo.85.6.670
Munro, 1999, Oral granisetron for strabismus surgery in children, Can J Anaesth, 46, 45, 10.1007/BF03012513
Johnson, 1–4, 2003, A cross-cultural survey of nurses, from Oncology Nursing Society (ONS), European Oncology Nursing Society (EONS) and Multinational Association of Supportive Care in Cancer (MASCC): perception of workload, time constraints and implications for optimising antiemetic treatment, Presented at the ONS Meeting
Perez, 1997, Efficacy and safety of oral granisetron versus IV ondansetron in prevention of moderately emetogenic chemotherapy-induced nausea and vomiting, Proc Am Soc Clin Oncol, 16, 43a
Gandara, 1998, Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy: dose, schedule, and route of administration, Support Care Cancer, 6, 237, 10.1007/s005200050160
Jordan, 18–21, 2003, A meta-analysis comparing the available 5-HT3-receptor antagonists as prophylactic agents for acute chemotherapy-induced emesis, Presented at the MASCC/ISOO Meeting
Farley, 2003, 5-HT3 antiemetic use in breast cancer patients receiving cyclophosphamide: a multicenter practice evaluation, Support Care Cancer, 11, 392